J B Chemicals & Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 15, 2025, 2:57 pm

Competitors of J B Chemicals & Pharmaceuticals Ltd

All Competitor Stocks of J B Chemicals & Pharmaceuticals Ltd

Quarterly Result

Last Updated: August 1, 2025, 6:55 pm

Below is a detailed analysis of the quarterly data for J B Chemicals & Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,094.00 Cr.. The value appears strong and on an upward trend. It has increased from 949.00 Cr. (Mar 2025) to 1,094.00 Cr., marking an increase of 145.00 Cr..
• For Expenses, as of Jun 2025, the value is 793.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 723.00 Cr. (Mar 2025) to 793.00 Cr., marking an increase of 70.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 301.00 Cr.. The value appears strong and on an upward trend. It has increased from 226.00 Cr. (Mar 2025) to 301.00 Cr., marking an increase of 75.00 Cr..
• For OPM %, as of Jun 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 24.00% (Mar 2025) to 28.00%, marking an increase of 4.00%.
• For Other Income, as of Jun 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 1.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 43.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 46.00 Cr. (Mar 2025) to 43.00 Cr., marking a decrease of 3.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 272.00 Cr.. The value appears strong and on an upward trend. It has increased from 193.00 Cr. (Mar 2025) to 272.00 Cr., marking an increase of 79.00 Cr..
• For Tax %, as of Jun 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00%.
• For Net Profit, as of Jun 2025, the value is 202.00 Cr.. The value appears strong and on an upward trend. It has increased from 146.00 Cr. (Mar 2025) to 202.00 Cr., marking an increase of 56.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 12.97. The value appears strong and on an upward trend. It has increased from 9.36 (Mar 2025) to 12.97, marking an increase of 3.61.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:06 am

Growth

Last Updated: September 5, 2025, 8:10 am

Balance Sheet

Last Updated: July 25, 2025, 2:58 pm

Below is a detailed analysis of the balance sheet data for J B Chemicals & Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
• For Reserves, as of Mar 2025, the value is 3,418.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,908.00 Cr. (Mar 2024) to 3,418.00 Cr., marking an increase of 510.00 Cr..
• For Borrowings, as of Mar 2025, the value is 28.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 378.00 Cr. (Mar 2024) to 28.00 Cr., marking a decrease of 350.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 804.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 687.00 Cr. (Mar 2024) to 804.00 Cr., marking an increase of 117.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 4,265.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,988.00 Cr. (Mar 2024) to 4,265.00 Cr., marking an increase of 277.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,968.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,004.00 Cr. (Mar 2024) to 1,968.00 Cr., marking a decrease of 36.00 Cr..
• For CWIP, as of Mar 2025, the value is 63.00 Cr.. The value appears to be declining and may need further review. It has decreased from 76.00 Cr. (Mar 2024) to 63.00 Cr., marking a decrease of 13.00 Cr..
• For Investments, as of Mar 2025, the value is 345.00 Cr.. The value appears to be declining and may need further review. It has decreased from 388.00 Cr. (Mar 2024) to 345.00 Cr., marking a decrease of 43.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,889.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,519.00 Cr. (Mar 2024) to 1,889.00 Cr., marking an increase of 370.00 Cr..
• For Total Assets, as of Mar 2025, the value is 4,265.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,988.00 Cr. (Mar 2024) to 4,265.00 Cr., marking an increase of 277.00 Cr..

Notably, the Reserves (3,418.00 Cr.) exceed the Borrowings (28.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for J B Chemicals & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 42.45. This value is within the healthy range. It has increased from 35.66 (Mar 24) to 42.45, marking an increase of 6.79.
• For Diluted EPS (Rs.), as of Mar 25, the value is 41.56. This value is within the healthy range. It has increased from 34.85 (Mar 24) to 41.56, marking an increase of 6.71.
• For Cash EPS (Rs.), as of Mar 25, the value is 53.36. This value is within the healthy range. It has increased from 44.52 (Mar 24) to 53.36, marking an increase of 8.84.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 220.54. It has increased from 188.36 (Mar 24) to 220.54, marking an increase of 32.18.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 220.54. It has increased from 188.36 (Mar 24) to 220.54, marking an increase of 32.18.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 251.67. It has increased from 224.50 (Mar 24) to 251.67, marking an increase of 27.17.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 68.74. This value is within the healthy range. It has increased from 60.19 (Mar 24) to 68.74, marking an increase of 8.55.
• For PBIT / Share (Rs.), as of Mar 25, the value is 57.76. This value is within the healthy range. It has increased from 51.28 (Mar 24) to 57.76, marking an increase of 6.48.
• For PBT / Share (Rs.), as of Mar 25, the value is 57.00. This value is within the healthy range. It has increased from 48.42 (Mar 24) to 57.00, marking an increase of 8.58.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 42.37. This value is within the healthy range. It has increased from 35.61 (Mar 24) to 42.37, marking an increase of 6.76.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.37. This value is within the healthy range. It has increased from 35.61 (Mar 24) to 42.37, marking an increase of 6.76.
• For PBDIT Margin (%), as of Mar 25, the value is 27.31. This value is within the healthy range. It has increased from 26.81 (Mar 24) to 27.31, marking an increase of 0.50.
• For PBIT Margin (%), as of Mar 25, the value is 22.94. This value exceeds the healthy maximum of 20. It has increased from 22.84 (Mar 24) to 22.94, marking an increase of 0.10.
• For PBT Margin (%), as of Mar 25, the value is 22.64. This value is within the healthy range. It has increased from 21.56 (Mar 24) to 22.64, marking an increase of 1.08.
• For Net Profit Margin (%), as of Mar 25, the value is 16.83. This value exceeds the healthy maximum of 10. It has increased from 15.86 (Mar 24) to 16.83, marking an increase of 0.97.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.83. This value is within the healthy range. It has increased from 15.86 (Mar 24) to 16.83, marking an increase of 0.97.
• For Return on Networth / Equity (%), as of Mar 25, the value is 19.21. This value is within the healthy range. It has increased from 18.90 (Mar 24) to 19.21, marking an increase of 0.31.
• For Return on Capital Employeed (%), as of Mar 25, the value is 24.69. This value is within the healthy range. It has decreased from 25.45 (Mar 24) to 24.69, marking a decrease of 0.76.
• For Return On Assets (%), as of Mar 25, the value is 15.43. This value is within the healthy range. It has increased from 13.83 (Mar 24) to 15.43, marking an increase of 1.60.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.12 (Mar 24) to 0.00, marking a decrease of 0.12.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.94. It has increased from 0.92 (Mar 24) to 0.94, marking an increase of 0.02.
• For Current Ratio (X), as of Mar 25, the value is 3.04. This value exceeds the healthy maximum of 3. It has increased from 2.13 (Mar 24) to 3.04, marking an increase of 0.91.
• For Quick Ratio (X), as of Mar 25, the value is 2.20. This value exceeds the healthy maximum of 2. It has increased from 1.56 (Mar 24) to 2.20, marking an increase of 0.64.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 1.75 (Mar 24) to 7.60, marking an increase of 5.85.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 35.93. This value is within the healthy range. It has increased from 28.40 (Mar 24) to 35.93, marking an increase of 7.53.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 28.53. This value is within the healthy range. It has increased from 22.72 (Mar 24) to 28.53, marking an increase of 5.81.
• For Earning Retention Ratio (%), as of Mar 25, the value is 64.07. This value is within the healthy range. It has decreased from 71.60 (Mar 24) to 64.07, marking a decrease of 7.53.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 71.47. This value exceeds the healthy maximum of 70. It has decreased from 77.28 (Mar 24) to 71.47, marking a decrease of 5.81.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 91.24. This value is within the healthy range. It has increased from 21.07 (Mar 24) to 91.24, marking an increase of 70.17.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 57.24. This value is within the healthy range. It has increased from 13.47 (Mar 24) to 57.24, marking an increase of 43.77.
• For Enterprise Value (Cr.), as of Mar 25, the value is 25,138.28. It has decreased from 25,860.24 (Mar 24) to 25,138.28, marking a decrease of 721.96.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.42. This value exceeds the healthy maximum of 3. It has decreased from 7.42 (Mar 24) to 6.42, marking a decrease of 1.00.
• For EV / EBITDA (X), as of Mar 25, the value is 23.49. This value exceeds the healthy maximum of 15. It has decreased from 27.68 (Mar 24) to 23.49, marking a decrease of 4.19.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.45. This value exceeds the healthy maximum of 3. It has decreased from 7.35 (Mar 24) to 6.45, marking a decrease of 0.90.
• For Retention Ratios (%), as of Mar 25, the value is 64.06. This value is within the healthy range. It has decreased from 71.59 (Mar 24) to 64.06, marking a decrease of 7.53.
• For Price / BV (X), as of Mar 25, the value is 7.36. This value exceeds the healthy maximum of 3. It has decreased from 8.76 (Mar 24) to 7.36, marking a decrease of 1.40.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.45. This value exceeds the healthy maximum of 3. It has decreased from 7.35 (Mar 24) to 6.45, marking a decrease of 0.90.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness